icon-account icon-glass


Call us for seroxat withdrawal information   


Have you tried to get off Seroxat only to suffer the Seroxat Withdrawal symptoms that drove you back on Seroxat? Or have you tried what you through was a slow Seroxat Taper and yet had to increase your dose to control the Seroxat Withdrawal symptoms?  The Royal College of Psychiatrists have warned that coming off antidepressant can cause symptoms lasting for months and that doses should be gradually lowered over months.  Our nonprofit has helped people in 78 countries and every state of the United States to come off Seroxat using a holistic approach that not only helps to ease Seroxat Withdrawal but assists in your body healing  as you gently get off Seroxat.  We know many herbs, over-the-counter and even many vitamins can interact with Seroxat and we take an individual approach to each client to ensure you stay safe.  Seroxat is known to be more challenging than most antidepressants so please, don't attempt to do a Seroxat Taper without professional guidance. Let us help you Taper off Seroxat at home.  CONTACT us today for a FREE consultation.*


how it


Our Seroxat weaning program is a slow taper that allows you to safely step down from Seroxat under the guidance of Our Team, Your Physician and Pharmacist. The Pre-Taper is for Symptom Relief. You will not wean  Seroxat until you feel better. This is where our Advanced Nutraceuticals are critical. Point of Return provides healthy, Drug-Free Strategies to help ease Seroxat withdrawal and support well-being.*

Our areas of expertise are Antidepressants, Benzodiazepines, Sleeping Pills and Painkillers on a case-by-case basis. Our In-Home programs are individualized based on your situation. An assessment is done once you start the Seroxat Withdrawal Program which allows us to individualize your gameplan based on age; length of time on the medications; health challenges; lifestyle, stress levels; additional medications; goals; and interactions. Don't Wean Seroxat alone, work with our Prescription Drug Experts.*

Imagine being Free of Seroxat Dependency 

- Proven Withdrawal Program completed In-Home with Expert Guidance

- Slowly Taper Seroxat

- All-Natural Nutraceuticals to Help Ease Seroxat Withdrawal*

- Professional Information on Interactions

- Free Mentoring on our 24/7 Private Discussion Board

- Free Assessment Upon Starting our Program (a $400 value)

Enter Discount Code ADFree for FREE Ground Shipping on your Withdrawal Program. *USA & Canada Only. 




Is it Your Time to Start a New Journey?


Debbie - Seroxat Withdrawal Success Story

"I give the glory to God for directing my path to Alesandra and to Point of Return!"  More...

Debbie (Seroxat Withdrawal Success Story)

Laurie - Seroxat Taper Success

"Thank you, again, for answering my constant barrage of questions, for being there when I was scared, for celebrating with me. And, most of all, for helping me get my life back." More...

Laurie (Seroxat Withdrawal Success Story)

Dan - Seroxat Withdrawal Success

"I still can't believe it. After 15 years I am finally med free thanks to the Point of Return team!!!!!" More...

Dan (Seroxat Withdrawal Success Story)

I had the ideal experience, because I felt literally zero withdrawal symptoms. I'm so grateful for not just the program itself but the quality of people that work for this company. More...

—Mike (Seroxat Withdrawal Success Story)

I am one of the survivors. For this I am grateful beyond words can truly express!  I can now say that I'm "SEROXAT FREE!" More...

Mike (Seroxat (Paxil) Withdrawal Success Story)

                                using a Natural Approach

Our team has survived psychoactive drug withdrawal. More...

  We have helped people in 78 countries and in every state of the USA. More...

We have extensive media coverage; television, print, radio. More...


Message sent, thanks! Will get back to your shortly.







Seroxat (Paxil) l is one of the most potent of the SSRIs (Selective Serotonin Reuptake Inhibitors) and has shown a high incidence of dependence. Seroxat (Paxil) is associated with a high incidence and severity of withdrawal symptoms (discontinuation syndrome) and therefore it is recommended to taper gradually to help minimize the discomfort. 

Seroxat was derived from Paroxetine, which was originally developed by Ferrosan, a Danish company who began researching the compound in the 1960s. By the 1970s Ferroson developed a paroxetine formula, called the ‘Buus-Lassen compound’, and patented it in the United States in 1977. SmithKline Pharmaceuticals bought the rights and research in 1980, made revisions and patented the new paroxetine formula in 1986.

The clinical trials were performed in under-developed countries and the results were called less-than-desired by industry insiders. SmithKline was able to compile sufficient positive data to obtain an FDA approval for the brand name Paxil in 1992 and by 2007 was the 5th most prescribed antidepressant drug in the United States. 

 GlaxoSmithKline marketed the drug extensively as “non-habit forming” and yet this was proven to be false by numerous experts. More recently FDA scientists and other research institutions discovered that taking Seroxat (Paxi) during pregnancy could dramatically increase the risk of serious birth defects including heart, lung, brain and spine defects, skull deformities, club foot, and abdominal defects. The FDA issued a Public Health Advisory for the use of Seroxat (Paxi) during pregnancy and deemed a Category D pregnancy risk was required, meaning that there is clear risk to a human fetus when Paxil is taken during gestation. This category change, Public Health Advisory and notice to physicians all came after the drug had been on the market for more than 10 years. 

The manufacturer of Seroxat (Paxi) was issued more than 40 warnings from drug regulatory agencies in seven countries concerning hazardous consequences to Seroxat (Paxi) use, including Seroxat (Paxi) Withdrawal. Consumers across the country claim they have suffered severe Seroxat (Paxi) Withdrawal symptoms. 

Seroxat (Paxi) is associated with a high incidence and severity of withdrawal symptoms (discontinuation syndrome) and therefore it is recommended to taper gradually to minimize the discomfort. 

top of page



aggression, anxiety, balance issues , blurred vision, brain zaps, concentration impairment, constipation, crying spells, depersonalization, diarrhea, dizziness. electric shock sensations, fatigue, flatulence, flu-like symptoms, hallucinations, hostility, highly emotional, indigestion, irritability, impaired speech, insomnia, jumpy nerves, lack of coordination, lethargy, migraine headaches / increased headaches, nausea, nervousness, over-reacting to situations, paranoia, repetitive thoughts or songs, sensory & sleep disturbances, severe internal restlessness (akathisia), stomach cramps, tremors, tinnitus (ear ringing or buzzing), tingling sensations, troubling thoughts, visual hallucinations / illusions, vivid dreams, speech or visual changes, worsened depression 


abnormal dreams, abnormal ejaculation or orgasm, anxiety, appetite loss, blurred vision, chills, constipation, diarrhea, dizziness, dry mouth, frequent urination, flushing, gas, headache, impotence, infection, insomnia, muscle tension, nausea, nervousness, rash, sleepiness, sweating, tingling feeling, tremor, upset stomach, vomiting, weakness, yawning, abnormal taste, abnormal thinking, agitation, chest pain, confusion, decreased sex drive, depression, dilated pupils, dizziness upon standing up, high blood pressure, itching, loss of identity, rapid heartbeat, ringing in the ears, trauma, twitching, urinary problems, weight loss


Severe: visual impairment, muscle paralysis, bradycardia, angioedema, anaphylactoid reactions, bronchospasm, keratoconjunctivitis, pancreatitis, proteinuria, peptic ulcer, hematemesis, GI obstruction, ileus, akinesia, torticollis, coma, myelitis, seizures, myocardial infarction, stroke, atrial fibrillation, heart failure, pulmonary embolism, thrombosis, erythema nodosum, erythema multiforme, exfoliative dermatitis, pulmonary fibrosis, pulmonary edema, hearing loss, retinal hemorrhage, ocular hypertension, ocular hemorrhage, oliguria, epididymitis, hyperkalemia, laryngospasm, Guillain-Barre syndrome, SIADH, vasculitis, agranulocytosis, aplastic anemia, GI bleeding, pancytopenia, hemolytic anemia, ventricular fibrillation, torsade de pointes, ventricular tachycardia, pulmonary hypertension, toxic epidermal necrolysis, Stevens-Johnson syndrome, Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS), optic neuritis, hepatic necrosis, porphyria, renal failure (unspecified), serotonin syndrome, bone fractures, teratogenesis, neonatal abstinence syndrome, persistent pulmonary hypertension of the newborn 

Moderate: ejaculation dysfunction , constipation, impotence (erectile dysfunction), peripheral vasodilation, blurred vision, hypertonia, myoclonia, chest pain (unspecified), palpitations, dysuria, amnesia, memory impairment, hypertension, sinus tachycardia, myopathy, teeth grinding (bruxism), stomatitis, colitis, dysphagia, melena, gastritis, hemorrhoids, dyskinesia, dystonic reaction, nystagmus, ataxia, neuropathic pain, confusion, migraine, lymphadenopathy, anemia, leukopenia, eosinophilia, hematoma, orthostatic hypotension, hypotension, supraventricular tachycardia (SVT), angina, edema , contact dermatitis, atopic dermatitis, dyspnea, conjunctivitis, elevated hepatic enzymes, vaginitis, urinary retention, pyuria, urinary incontinence, cystitis, myasthenia, peripheral edema, oral ulceration, sialadenitis, gingival hyperplasia, glossitis, cholelithiasis, fecal incontinence, esophagitis, choreoathetosis, dysarthria, trismus, hyperalgesia, hyperreflexia , meningitis, aphasia, neuritis, hyponatremia, thrombocytopenia, lymphopenia, prolonged bleeding time, lymphocytosis, bundle-branch block, phlebitis, candidiasis, furunculosis, skin ulcer, bullous rash, hemoptysis, dysphonia, amblyopia, blepharitis, hyperacusis, cataracts, exophthalmos, photophobia, hyperbilirubinemia, jaundice, hepatitis, vaginal bleeding, prostatitis, nephrolithiasis, flank pain, tetany, hypothyroidism, hyperthyroidism, diabetes mellitus, goiter, hyperglycemia, hypoglycemia, hypercalcemia, hypokalemia, hypercholesterolemia, hypocalcemia, gout, dehydration, hyperphosphatemia, osteoporosis , withdrawal, akathisia, bleeding, platelet dysfunction, pneumonitis, hepatomegaly, hyperprolactinemia, priapism, galactorrhea, hematuria, osteopenia, growth inhibition 

Mild: headache, nausea, insomnia, drowsiness, asthenia, diarrhea, xerostomia, dizziness, libido decrease, tremor, hyperhidrosis, anorexia, orgasm dysfunction, sinusitis, infection, abdominal pain, flatulence, dyspepsia, yawning, dysmenorrhea, back pain, myalgia, malaise, fatigue, lethargy, appetite stimulation, paresthesias, pharyngitis, rhinitis, weight gain, vomiting, rash. increased urinary frequency, chills, cough, fever, dysgeusia, arthralgia, gingivitis, dental pain, eructation, gastroesophageal reflux, weight loss, hyperkinesis, vertigo, hypoesthesia, purpura, leukocytosis, ecchymosis, syncope, photosensitivity, acne vulgaris, urticaria, xerosis, alopecia, hyperventilation, laryngitis, ocular pain, mydriasis, otalgia, amenorrhea, libido increase, menorrhagia, urinary urgency, polyuria, nocturia, polydipsia, dental caries, tongue discoloration, hyporeflexia, pallor, hypothermia, skin discoloration, seborrhea, vesicular rash, maculopapular rash, hirsutism, hiccups, diplopia, parosmia, ptosis, gynecomastia, leukorrhea, mastalgia, breast enlargement, breast discharge, pelvic pain, muscle cramps, pruritus, tinnitus, restless legs syndrome (RLS), petechiae  


Children, growth inhibition, suicidal ideation

PAXIL is not FDA-approved for use in children and adolescents less than 18 years of age. According to the FDA, there are 3 well-controlled trials that have shown PAXIL is no more effective than placebo for the treatment of depression in pediatric patients. In October 2004, the FDA directed manufacturers of all antidepressants to include a boxed warning detailing the risk of suicide in pediatric patients with MDD and other psychiatric disorders (OCD, social anxiety disorder). A causal role has been established for antidepressants in inducing suicidality in pediatric patients. The risk of suicidality for these drugs was identified in a pooled analysis of 24 placebo-controlled trials (n = 4,400) lasting up to 16 weeks in pediatric patients with major depressive disorder (MDD), obsessive compulsive disorder (OCD), or other psychiatric disorders. The analysis showed a greater risk of suicidality during the first few months of treatment in those receiving antidepressants (SSRIs and others). The average risk of such events on drug was 4% and 2% for placebo; however, no suicides occurred in these trials. Pooled analysis of short-term clinical trials during early phase treatment of SSRIs and other antidepressants in young adults (18 to 24 years) also showed an increased risk of suicidal thinking and behavior. The clinical need for an antidepressant in children or young adults for any use must be weighed against the risk of increased suicidality; patients who are started on therapy should be observed closely for clinical worsening, suicidality, or unusual changes in behavior, particularly within the first few months of starting therapy or at the time of dose increase or decrease. It is unknown if the suicidality risk in children and young adults extends to longer-term therapy (i.e., beyond several months). In a meta-analysis conducted by the manufacturer in adult patients with and without psychiatric disorders, a higher frequency of suicidal behavior occurred in young adults and adults treated with paroxetine compared with placebo. This difference was statistically significant; however, as the number of events were small, these data should be interpreted with caution. All of the reported events of suicidal behavior in the adult patients with depression were non-fatal suicide attempts, and the majority of these attempts (8 of 11) were in younger adult patients. The possibility of a suicide attempt is inherent in all patients with depressive symptoms, whether these occur in primary depression or in association with another primary disorder such as OCD. All patients with a history of suicidal ideation or behaviors and those with a prominence of suicidal ideation prior to treatment are considered at an increased risk for suicidal ideation or attempts, and should be closely monitored during treatment with paroxetine. In patients who exhibit changes in symptoms, worsening of depression or suicidality, a decision should be made to change or discontinue treatment. If discontinuing, the medication should be tapered as rapidly as possible, but with recognition that abrupt discontinuation can also cause adverse symptoms. All antidepressants should be prescribed in the smallest quantity consistent with good patient management in order to reduce the risk of overdose. The potential for growth inhibition in pediatric patients should be monitored during SSRI therapy; monitor height and weight periodically. Data are inadequate to determine whether the chronic use of SSRIs causes long-term growth inhibition; however, decreased weight gain has been observed in children and adolescents receiving paroxetine.

top of page


 Per the FDA:

If the decision has been made to discontinue treatment, medication should be tapered, as rapidly as is feasible, but with recognition that abrupt discontinuation can be associated with certain symptoms (see PRECAUTIONS and DOSAGE AND ADMINISTRATION: Discontinuation of Treatment With PAXIL, for a description of the risks of discontinuation of PAXIL).

Symptoms associated with discontinuation of PAXIL (Seroxat) have been reported (see PRECAUTIONS: Discontinuation of Treatment With PAXIL). Patients should be monitored for these symptoms when discontinuing treatment, regardless of the indication for which PAXIL is being prescribed. A gradual reduction in the dose rather than abrupt cessation is Discontinuation of Treatment With PAXIL:  recommended whenever possible. If intolerable symptoms occur following a decrease in the dose or upon discontinuation of treatment, then resuming the previously prescribed dose may be considered. Subsequently, the physician may continue decreasing the dose but at a more gradual rate. 


*While great care has been taken in organizing and presenting the material throughout this website, please note that it is provided for informational purposes only and should not be taken as Medical Advice.

*The statements/info on this website have not been evaluated by the Food and Drug Administration (FDA). The products and labels mentioned / sold are not intended to diagnose, treat, cure, or prevent any disease or illness.

* Testimonial results may vary person to person.

*The program outlined in Point of Return is not meant to substitute your doctor, instead it is to be utilized With Your physician to help you with your drug withdrawal process and with his or her consent and support throughout.

*This program is not meant to cure or prevent any disease or illness.

*Because prescription medications can cause severe withdrawal reactions, do not stop taking any medication without first consulting your physician. The decision to taper any medication should be discussed with your doctor and done with their consent and support throughout the process. More..